As global tobacco use patterns evolve, smoking, vaping & harm-reduction science is gaining importance in public health and pulmonology. Traditional smoking cessation programs now coexist with research into electronic nicotine delivery systems (ENDS), heated tobacco products, and nicotine replacement therapies. While vaping is promoted by some as a harm-reduction tool, its long-term respiratory effects remain under investigation. Smoking, vaping & harm-reduction science highlights the need for balanced messaging, particularly for youth and high-risk populations. Epidemiologic studies and toxicologic analyses are essential in defining risk thresholds and shaping regulatory policies. Health education, tobacco taxation, and product labelling reforms play complementary roles in prevention efforts. A nuanced, evidence-based approach is vital to reducing global lung disease burden without inadvertently creating new dependencies.
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Non-canonical IRF3 functions in limiting pulmonary inflammation
Saurabh Chattopadhyay, University of Kentucky, United States
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : The representational challenge for designing and managing intelligent and ethical 5P medicine pulmonary, respiratory and lung health care systems
Habil Bernd Blobel, University of Regensburg, Germany
Title : From Chronic Obstructive Pulmonary Disease (COPD) to Non-Small Cell Lung Cancer (NSCLC): T helper cell epigenetic modifications and cancer risk
Koustav Sarkar, SRM Institute of Science and Technology, India
Title : Bacterial profile of community acquired pneumonia in a public health institute
Sayan Bhattacharyya, AIIH&PH, India